Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI-2)
Short Study Name (acronym): ADNI-2
Long Name: Alzheimer’s
Disease Neuroimaging Initiative 2
Investigators (list PI first): Kaycee
Agency: ADCS through NIA
Funding Dates: 09/30/2010 – 08/31/2017
questions or aims: The study aims are focused on predictors, outcomes and
clinical trial design, but fulfillment of these aims will add considerably to
what is known about the basic neuroscience of AD in terms of progression and
underlying mechanisms. Determine and define those
biomarkers which best predict future cognitive decline and conversion to
MCI/dementia at the various stages of the progression from normal cognition to
dementia. Determine and define those
biomarkers that best serve as outcome measures to quantify the rate of progress
at the various stages from controls to dementia.
Improve clinical trials by
developing various clinical trial protocol scenarios, which use clinical,
cognitive, and biomarker measures as selection criteria, as covariates, and as
outcome measures, with maximum statistical power to detect treatment effects.
Such scenarios would be developed for subjects with dementia, with MCI, with
mild symptomatology, subjects with significant memory concern but whose
neuropsychological test performance is within the normal range, and normal
As clinical trials are moving
toward less or asymptomatic individuals, a new cohort, subjects with
significant memory concerns have been included to address this shift.
Perform pathological examination on brains obtained by
autopsy to validate the antemortum diagnoses.
Target population: Male and female
age 55 - 90 years who meet the study criteria for early mild cognitive
impairment and have a reliable study partner.
Target # to enroll: 650 across the
US and Canada
(Target) Dates of enrollment: Closed
of assessments and questionnaires:
Study Website (if applicable): www.adni-info.org
Coordinator Contact Info: Leslie Gordineer